Suchen
Centessa Pharmaceuticals PLC
CNTAZur Watchlist hinzufügen
40.500USD
0.0000.00%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
6.27BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Centessa Pharmaceuticals PLC Unternehmen
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company. The Company is developing a new class of potential therapies within its orexin receptor 2 (OX2R) agonist program for the treatment of excessive daytime sleepiness (EDS), impaired attention, cognitive deficits, fatigue and other symptoms across neurological, neurodegenerative and neuropsychiatric disorders. It also has an early-stage immuno-oncology program focused on its LockBody technology platform. Its OX2R agonist pipeline includes ORX750, its advanced OX2R agonist development candidate, and ORX142, ORX489 and OX2R agonists in preclinical development. Its ORX750, an investigational, orally administered, highly potent and selective OX2R agonist, is in a Phase IIa study of participants with narcolepsy type 1 (NT1), NT2 and idiopathic hypersomnia (IH). ORX142 is the second OX2R agonist development candidate being advanced for the treatment of neurological and neurodegenerative disorders and other symptoms.
Centessa Pharmaceuticals PLC Informationen
BörsenkürzelCNTA
Name des UnternehmensCentessa Pharmaceuticals PLC
IPO-datumMay 28, 2021
CEOSaha (Saurabh)
Anzahl der mitarbeiter77
WertpapierartDepository Receipt
GeschäftsjahresendeMay 28
Addresse3rd Floor
StadtALTRINCHAM
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlWA14 2DT
Telefon447391789784
Websitehttps://www.centessa.com/
BörsenkürzelCNTA
IPO-datumMay 28, 2021
CEOSaha (Saurabh)
Führungskräfte von Centessa Pharmaceuticals PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Brett I. W. Zbar, M.D.
Dr. Brett I. W. Zbar, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Mary Lynne Hedley, Ph.D.
Dr. Mary Lynne Hedley, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Carol Stuckley
Ms. Carol Stuckley
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Arjun Goyal, M.D.
Dr. Arjun Goyal, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
462.58K
--
Dr. Saurabh Saha, M.D., Ph.D.
Dr. Saurabh Saha, M.D., Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
91.08K
+50.41%
Dr. Gregory M. (Greg) Weinhoff, M.D.
Dr. Gregory M. (Greg) Weinhoff, M.D.
Chief Business Officer
Chief Business Officer
3.89K
-1882.61%
Mr. Iqbal Hussain
Mr. Iqbal Hussain
General Counsel and Chief Compliance Officer, Company Secretary
General Counsel and Chief Compliance Officer, Company Secretary
--
--
Ms. Tia Bush
Ms. Tia Bush
Chief Technology and Quality Officer
Chief Technology and Quality Officer
--
--
Dr. Francesco de Rubertis, Ph.D.
Dr. Francesco de Rubertis, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Centessa Pharmaceuticals PLC?
Die fünf größten Anteilseigner von Centessa Pharmaceuticals PLC sind: Dr. Arjun Goyal, M.D.
Wie viele Institutionen halten Anteile an Centessa Pharmaceuticals PLC (CNTA)?
Mit Stand vom 2026Q1 halten 276 Institutionen Anteile an Centessa Pharmaceuticals PLC, mit einem Gesamtmarktwert von etwa 150.25M, was 97.10% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 12002120.00 gestiegen.
